Hayden Royal LLC acquired a new stake in shares of CVS Health Corp (NYSE:CVS) during the second quarter, according to its most recent filing with the SEC. The fund acquired 4,664 shares of the pharmacy operator’s stock, valued at approximately $270,000.

Several other large investors also recently added to or reduced their stakes in CVS. Capital Investment Advisory Services LLC increased its position in shares of CVS Health by 3.8% during the 1st quarter. Capital Investment Advisory Services LLC now owns 5,128 shares of the pharmacy operator’s stock valued at $277,000 after purchasing an additional 189 shares during the last quarter. Virginia National Bank increased its position in shares of CVS Health by 4.9% during the 1st quarter. Virginia National Bank now owns 4,100 shares of the pharmacy operator’s stock valued at $221,000 after purchasing an additional 190 shares during the last quarter. Burke & Herbert Bank & Trust Co. increased its position in shares of CVS Health by 2.8% during the 1st quarter. Burke & Herbert Bank & Trust Co. now owns 7,466 shares of the pharmacy operator’s stock valued at $402,000 after purchasing an additional 200 shares during the last quarter. First Command Financial Services Inc. increased its position in shares of CVS Health by 16.0% during the 2nd quarter. First Command Financial Services Inc. now owns 1,464 shares of the pharmacy operator’s stock valued at $80,000 after purchasing an additional 202 shares during the last quarter. Finally, Hudock Capital Group LLC increased its position in shares of CVS Health by 54.0% during the 2nd quarter. Hudock Capital Group LLC now owns 576 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 202 shares during the last quarter. Institutional investors own 77.18% of the company’s stock.

Shares of CVS stock opened at $59.85 on Wednesday. The stock has a market cap of $77.11 billion, a PE ratio of 8.45, a PEG ratio of 1.30 and a beta of 0.90. CVS Health Corp has a 1-year low of $51.72 and a 1-year high of $82.15. The firm’s 50-day moving average is $56.12. The company has a debt-to-equity ratio of 1.39, a current ratio of 0.95 and a quick ratio of 0.64.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, August 7th. The pharmacy operator reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.19. The company had revenue of $63.43 billion during the quarter, compared to analysts’ expectations of $62.66 billion. CVS Health had a return on equity of 16.15% and a net margin of 1.91%. CVS Health’s quarterly revenue was up 35.2% compared to the same quarter last year. During the same period in the prior year, the business posted $1.69 EPS. Research analysts anticipate that CVS Health Corp will post 6.96 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 2nd. Shareholders of record on Thursday, July 25th were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 3.34%. The ex-dividend date of this dividend was Wednesday, July 24th. CVS Health’s dividend payout ratio (DPR) is currently 28.25%.

CVS has been the topic of several recent research reports. UBS Group reduced their price objective on CVS Health from $74.00 to $67.00 and set a “sell” rating on the stock in a research report on Thursday, May 2nd. Morgan Stanley reiterated a “buy” rating and set a $74.00 price objective on shares of CVS Health in a research report on Sunday. Cantor Fitzgerald reiterated a “buy” rating and set a $80.00 price objective on shares of CVS Health in a research report on Wednesday, May 1st. Guggenheim initiated coverage on CVS Health in a research report on Thursday, April 18th. They set a “buy” rating and a $75.00 price objective on the stock. Finally, BMO Capital Markets set a $63.00 price objective on CVS Health and gave the company a “hold” rating in a research report on Friday, May 3rd. Two analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $75.14.

CVS Health Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Recommended Story: FAANG Stocks

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.